# Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

> **NCT07581704** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Christopher Strouse** · enrollment: 10 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Sirolimus
- **BIOLOGICAL:** Teclistamab
- **BIOLOGICAL:** Talquetamb

## Key facts

- **NCT ID:** NCT07581704
- **Lead sponsor:** Christopher Strouse
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2029-05-01
- **Final completion:** 2029-09-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07581704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07581704, "Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT07581704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*